EXACT Therapeutics initiates preclinical immunotherapy collaboration with Agenus Inc.
Oslo, Norway, October 8, 2024 - EXACT Therapeutics AS (Euronext Growth: EXTX), a clinical stage precision medicine company utilizing the power of ultrasound to enable targeted drug delivery in oncology, today announced a preclinical research collaboration with Agenus Inc. (NASDAQ: AGEN) to explore the combination of Agenus’ proprietary immune checkpoint inhibitors in combination with EXACT’s Acoustic Cluster Technology, ACT®, in pancreatic cancer models.
The project substantiates EXACT’s work in cancer-immunotherapy, which is the leading type of cancer treatment, and which helps your immune system fight cancer. Further, it is an extension of the company’s announcement on September 25, 2024 of the grant of EXACT’s first immunotherapy patent.
Commenting on the announcement, Per Walday, CEO of EXACT Therapeutics, said: "We are excited to initiate a preclinical collaboration with Agenus Inc., a late-stage oncology-focused biotechnology company. The collaboration is a recognition of the promising results EXACT Therapeutics has demonstrated in its preclinical work in pancreatic tumor models and in the Phase 1 ACTIVATE trial in patients with liver metastases of colorectal origin."
For further information, please contact:
Per Walday
CEO EXACT Therapeutics
Email: per.walday@exact-tx.com
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
About EXACT Therapeutics
EXACT is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to enable or significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com
About ACT®
• ACT is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent.
• ACT is being tested in the clinic and has released positive interim data. It is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration.
• Initial focus of the company is oncology. The ACT platform has potential across many therapeutic areas (including CNS, immunotherapy) and product classes.
Forward looking statements:
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.